SUBSCRIBE: Print / eNewsletter
Cancer Network presents exclusive coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Check out some of our topic specific ASCO coverage:
SELECT Subanalyses Provide Patient Selection Insight for Lenvatinib
Two subgroup analyses of the SELECT trial could help clarify which differentiated thyroid carcinoma patients will benefit most from lenvatinib.
EXAM: Cabozantinib Doubled Survival in Medullary Thyroid Carcinoma With RET M918T Mutation
In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.
Everolimus Active in Thyroid Cancer After Sorafenib Progression
Adding everolimus to sorafenib at the time of progression of advanced radio-iodine refractory differentiated thyroid carcinoma was tolerable and active.
Transcriptional Inhibitor With Doxorubicin Shows Promise in SCLC
A phase I study showed that transcriptional inhibitor PM01183 with doxorubicin induced responses in patients with small-cell lung cancer.
First-Line Lenvatinib May Improve PFS in Thyroid Cancer
First-line lenvatinib may improve progression-free survival in patients with 131I-refractory differentiated thyroid cancer with no prior history of VEGF therapy.
Denosumab in Breast Cancer Patients Cut Fracture Rate in Half
Denosumab used as an adjuvant therapy in postmenopausal breast cancer patients on aromatase inhibitor therapy cut the risk of fractures in half.
WBRT Controls Brain Metastases But Does Not Impact Survival
Whole brain radiation therapy helps control tumor growth in patients with 1 to 3 small brain metastases, but it does not significantly extend patient survival.
Lenvatinib Plus Everolimus Improves Survival in Metastatic RCC
A combination of lenvatinib plus everolimus improved survival and overall response compared with everolimus alone in metastatic renal cell carcinoma patients.
Long-Term Data Show Ponatinib Effective, With Thrombotic Risk in CML
Ponatinib demonstrates continuing clinical activity in chronic-phase chronic myeloid leukemia patients who failed prior treatment with other TKIs.
Adding Olaratumab Dramatically Improves Survival in Soft-Tissue Sarcoma
Early trial results found that the addition of olaratumab to doxorubicin dramatically improves survival in patients with advanced soft-tissue sarcoma.